Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14067600 | 1.00 | CYP2C19 (0.71) | CYP2C19TSHRLMNAGAAKMT2A | |
| SCHEMBL31276312 | 0.89 | CYP2C19 (0.57) | CYP2C19TSHRLMNAGAAKMT2A | |
| Mephenytoin SCHEMBL21766 | 0.83 | CYP2C19 (1.00) | CYP2C19TSHRLMNAGAAKMT2A | |
| Mephenytoin SCHEMBL21768 | 0.83 | CYP2C19 (1.00) | CYP2C19TSHRLMNAGAAKMT2A | |
| SCHEMBL1331185 | 0.75 | CYP2C19 (0.45) | CYP2C19TSHRLMNAGAAKMT2A | |
| SCHEMBL14567470 | 0.75 | CYP2C19 (0.41) | CYP2C19TSHRLMNAGAAKMT2A | |
| SCHEMBL11092735 | 0.73 | MMP2 (0.51) | TSHR | |
| SCHEMBL31000378 | 0.63 | TSHR (0.47) | CYP2C19TSHRLMNAKMT2AFPR2 | |
| SCHEMBL29549519 | 0.62 | CYP2C19 (1.00) | CYP2C19TSHRLMNAGAAKMT2A | |
| SCHEMBL28812498 | 0.61 | MMP2 (0.59) | LMNAGAAKMT2ACNR1GPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097037-A1 | FUSED RING COMPOUND HAVING GLP-1 RECEPTOR AGONIST EFFECT | SHIONOGI & CO., LTD. (JP) | 2026-04-09 | — | — | US | disclosed |
| US-20260098031-A1 | MONOCYCLIC COMPOUND HAVING GLP-1 RECEPTOR AGONIST ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2026-04-09 | — | — | US | disclosed |
| EP-4592285-A1 | FUSED RING COMPOUND HAVING GLP-1 RECEPTOR AGONIST EFFECT | Shionogi & Co., Ltd. (JP) | 2025-07-30 | — | — | EP | disclosed |
| CN-119909076-A | Pharmaceutical composition of tricyclic compounds | 正大天晴药业集团股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-119841824-A | Crystal of tri-fused ring compound and application thereof | 正大天晴药业集团股份有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-119792296-A | Pharmaceutical composition of tricyclic compounds | 正大天晴药业集团股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| US-20240400560-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE HAVING VIRAL GROWTH INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | SHIONOGI & CO., LTD. (JP) | 2024-12-05 | — | — | US | disclosed |
| CN-114929700-B | Pharmaceutical compositions of tricyclic PDE3/PDE4 dual inhibitor compounds | 正大天晴药业集团股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-114929701-B | Crystal of PDE3/PDE4 dual inhibitor and application thereof | 正大天晴药业集团股份有限公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-114008051-B | Pyrazolopyrimidine sulfone inhibitors of JAK kinases and uses thereof | 豪夫迈·罗氏有限公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-3412663-B1 | NITROGEN-CONTAINING HETEROCYCLE AND CARBOCYCLE DERIVATIVES HAVING TRKA INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2022-09-07 | — | — | EP | disclosed |
| US-20220251113-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | SHIONOGI & CO., LTD. (JP) | 2022-08-11 | — | — | US | disclosed |
| EP-4028130-A1 | BENZYL AMINE-CONTAINING 5,6-HETEROAROMATIC COMPOUNDS USEFUL AGAINST MYCOBACTERIAL INFECTION | Shionogi & Co., Ltd (JP) | 2022-07-20 | — | — | EP | disclosed |
| WO-2022119899-A1 | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME BC1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN | SHIONOGI & CO., LTD. (JP) | 2022-06-09 | — | — | WO | disclosed |
| US-11345716-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | SHIONOGI & CO., LTD. (JP) | 2022-05-31 | — | — | US | disclosed |
| EP-3986899-A1 | PYRAZOLOPYRIMIDINE ARYL ETHER INHIBITORS OF JAK KINASES AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| EP-3986900-A1 | TETRAZOLE-SUBSTITUTED PYRAZOLOPYRIMIDINE INHIBITORS OF JAK KINASES AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| EP-3986901-A1 | PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| CN-104644628-B | A kind of native compound as antidiabetic medicine application | 清华大学 | 2017-06-06 | — | — | CN | disclosed |
| CN-104644628-A | Use of natural compound as anti-diabetes drug | UNIV TSINGHUA | 2015-05-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345716-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | DRD3, DRD4, DRD2 | CYP2C19 1842/4885TSHR 80/4885LMNA 3017/4885 |
| US-20220251113-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | DRD3, DRD4, DRD2 | CYP2C19 1842/4885TSHR 80/4885LMNA 3017/4885 |
| US-20260098031-A1 | MONOCYCLIC COMPOUND HAVING GLP-1 RECEPTOR AGONIST ACTIVITY | GLP1R, GCGR, CCKAR | CYP2C19 2363/4885TSHR 63/4885LMNA 2629/4885 |
| US-20260097037-A1 | FUSED RING COMPOUND HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, CCKAR, GCGR | CYP2C19 1882/4885TSHR 47/4885LMNA 2931/4885 |
| US-20240400560-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE HAVING VIRAL GROWTH INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | CTRL, ACE2, ACE | CYP2C19 573/4885TSHR 2457/4885LMNA 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.